Claims
- 1. A pharmaceutically acceptable topical antifungal and/or an anitmicrobial composition comprising:
a) an amount of pimaricin or a salt thereof that is effective to inhibit the growth of an infectious pathogen in a mammal; b) a pharmaceutically acceptable dipolar aprotic solvent or an acid; and c) a pharmaceutically acceptable aqueous secondary solvent, wherein the final composition is free or substantially free of the aprotic solvent and/or the acid.
- 2. The composition of claim 1, further comprising an ointment and/or a cream base.
- 3. The composition of claim 2, where the ointment base comprises one or more of petrolatum, mineral oil, ceresin, lanolin alcohol, panthenol, glycerin, bisabolol.
- 4. The composition of claim 1, where the acid is a carboxylic acid.
- 5. The composition of claim 4, where the carboxylic acid is acetic acid.
- 6. The composition of claim 1, where the aprotic solvent is DMA, DMSO, PEG or PE.
- 7. The composition of claim 1, where the aqueous secondary solvent is a surfactant.
- 8. The composition of claim 1, where the aqueous secondary solvent is an aqueous lipid emulsion.
- 9. The composition of claim 8, where the aqueous lipid emulsion comprises a lipid component that includes at least one vegetable oil and at least one fatty acid.
- 10. The composition of claim 9, where the lipid component comprises at least about 5% by weight soybean oil and at least about 50% by weight fatty acids.
- 11. The composition of claim 1, where the secondary solvent is water.
- 12. The composition of claim 1, where the secondary solvent is saline solution.
- 13. The composition of claim 1, where the secondary solvent is dextrose solution.
- 14. A method of preventing or treating a localized infection in a mammal, comprising administering to a mammal a pharmaceutically acceptable composition of any one of claims 1-13.
- 15. The method of claim 14, wherein the administering is topical.
- 16. The method of claim 14, wherein the administering is by inhalation.
- 17. The method of claim 14, wherein the localized infection is a vaginal infection, a perirectal infection, a skin infection, an infection of the ingunal area, a mucosal infection, an intertriginous infection, a scalp infection, an infection of the outer ear canal, or a respiratory tract infection.
- 18. An antifungal and/or an antimicrobial composition pharmaceutically acceptable for local administration, comprising:
a) an amount of pimaricin or a salt thereof effective to inhibit the growth of a pathogen in a mammal; b) acetic acid; and c) an aqueous secondary solvent.
- 19. The composition of claim 18, wherein the acetic acid is further removed to make the final composition free or substantially free of acetic acid.
- 20. The composition of claim 18, wherein the aqueous secondary solvent is a lipid emulsion that comprises at least one vegetable oil and at least one fatty acid.
- 21. The composition of claim 18, wherein the aqueous secondary solvent is a surfactant.
- 22. The composition of claim 18, wherein the composition further comprises an ointment and/or a cream base.
- 23. The composition of claim 18, where the ointment base comprises one or more of petrolatum, mineral oil, ceresin, lanolin alcohol, panthenol, glycerin, bisabolol.
- 24. A method of preventing or treating a local infection in a mammal, comprising the step of administering topically to a mammal a composition as in any one of claims 18-23.
- 25. A pharmaceutically acceptable antifungal and/or antimicrobial composition which is substantially free of aprotic solvents or acids prepared by the method comprising:
a) obtaining pimaricin or a salt thereof; b) dissolving the pimaricin in a pharmaceutically acceptable dipolar aprotic solvent or a acid; c) further dissolving the composition of step b) in a pharmaceutically acceptable aqueous secondary solvent; and d) removing the dipolar aprotic solvent or the acid from said composition.
- 26. The composition of claim 25, where the method further comprises adding to the composition an ointment and/or a cream base.
- 27. The composition of claim 25, where the acid is acetic acid.
- 28. The composition of claim 25, where the aprotic solvent is selected from the group comprising DMSO, DMA, PE, or PEG.
- 29. The composition of claim 25, where the aqueous secondary solvent is a surfactant.
- 30. The composition of claim 25, where the aqueous secondary solvent is an aqueous lipid emulsion.
- 31. The composition of claim 30, where the aqueous lipid emulsion comprises a lipid component that includes at least one vegetable oil and at least one fatty acid.
- 32. The composition of claim 31, where the lipid component comprises at least about 5% by weight soybean oil and at least about 50% by weight fatty acids.
- 33. The composition of claim 25, where the secondary solvent is water.
- 34. The composition of claim 25, where the secondary solvent is saline solution.
- 35. The composition of claim 25, where the secondary solvent is dextrose solution.
- 36. The composition of claim 25, where the removing the dipolar aprotic solvent or the acid from the composition is by lyophilization or neutralization with base.
BACKGROUND OF THE INVENTION
[0001] The present application claims priority to co-pending U.S. Patent Application Serial No. 60/332,806, filed Nov. 14, 2001. The entire text of the above-referenced disclosure is specifically incorporated by reference herein without disclaimer.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60332806 |
Nov 2001 |
US |